finasteride efficacy safety PCOS hirsutism treatment, finasteride polycystic ovary syndrome androgen excess, 5-alpha reductase inhibitor finasteride hyperandrogenism women, finasteride hirsutism treatment PCOS safety concerns, antiandrogen therapy finasteride women reproductive age, finasteride versus other antiandrogens PCOS management, Durmusoglu Erenus finasteride efficacy safety letter, finasteride female hyperandrogenism clinical evidence, 5-alpha reductase inhibitor women androgen-related symptoms, finasteride fertility safety reproductive endocrinology
PMID 9091357 9091357 DOI 10.1016/s0015-0282(97)80100-8 10.1016/s0015-0282(97)80100-8
Keywords
Enzyme Inhibitors/adverse Effects/therapeutic Use, Female, Finasteride/adverse Effects/therapeutic Use, Hirsutism/blood/drug Therapy, Humans, Patient Selection, Polycystic Ovary Syndrome/diagnostic Imaging/drug Therapy, Reproducibility of Results, Testosterone/blood, Ultrasonography, Enzyme Inhibitors, Testosterone, Finasteride